News | January 24, 2026
Akums bags key EU GMP certifications for 2 Haridwar plants
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Akums invested Rs. 272 crore in capital expenditure during FY25
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Branded formulation business continues to perform well across domestic and export markets
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Subscribe To Our Newsletter & Stay Updated
